The Study That Made Headlines

In November 2020, a team at Tel Aviv University led by Professor Shai Efrati published a study in Aging that sent ripples through the longevity community. After 60 HBOT sessions (90 minutes each, at 2 ATA with 100% oxygen), 35 healthy adults aged 64+ showed telomere lengthening of 20-38% in certain immune cells, along with a 10-37% decrease in senescent (zombie) cells.

This was the first study to demonstrate telomere lengthening through a non-pharmacological, non-genetic intervention in humans. The implications were enormous — if confirmed, HBOT could be one of the few interventions that actually reverses, rather than slows, a key hallmark of aging.

What the Study Actually Measured

The study measured telomere length in peripheral blood mononuclear cells (PBMCs) — specific immune cells, not all cells in the body. Telomeres are the protective caps at the ends of chromosomes that shorten with each cell division. Shorter telomeres are associated with increased disease risk and mortality.

Important Caveats

Before concluding that HBOT reverses aging, consider: the sample size was small (n=35), with no control group. The telomere changes were in specific immune cell populations, not whole-body. The study has not yet been replicated at scale. And telomere length is only one biomarker of aging — it does not capture the full picture.

Our Perspective

At GenoRyx, we offer HBOT because the evidence — while early — is genuinely promising. The Tel Aviv protocol (60 sessions) is the gold standard. We also see clinical improvements in energy, cognitive function, and recovery in our patients that extend beyond what telomere data alone would predict.

We believe in honest framing: HBOT is one of the most interesting tools in the longevity toolkit. It is not yet proven to extend human lifespan. If you are interested, our longevity physician can discuss whether a protocol is appropriate for your health goals.